Navigation Links
Edmonton to Host Clinical Trial for Nova Oculus Medical Device that Could Help Improve Vision for AMD Sufferers
Date:12/14/2018

NOVA OCULUS PARTNERS, LLC, and its Canadian partner, the Eye Machine Canada Inc., have been given the green light to immediately begin a clinical patient trial in Edmonton using their pioneering technology for treating Age-Related Macular Degeneration (AMD).

The medical devices bureau of Health Canada has granted what is called an Investigational Testing Authorization for the trial, while approval of the protocol and the study’s investigator has been given by the clinical trials committee of the Health Research Ethics Board of Alberta. Recruitment of the trial participants will begin immediately.

The clinical trial will be conducted independently in Edmonton by optometrist Dr. Brent Saik using the company’s Nova Oculus II device. Serving as investigator for the trial will be Dr. Michael Fielden, an ophthalmologist with the Calgary Retina Institute. The trial will be double-blind study involving 50 patients. A double-blind study is one in which neither the participants nor those administering the tests know whether the patient is receiving the actual treatment or a placebo. This procedure is utilized to prevent bias in research results.

How long the study will take is unknown. “We will conduct the trial as quickly as possible, but it is a complex trial with a challenging patient population,” said Walter O’Rourke, the Fergus, Ontario-based chief operating officer for Nova Oculus. “Our priority is the care of the trial participants and the production of good data.”

Results from the trial will play a key role in gaining regulatory approval in Canada for the Nova Oculus II device. It was designed and engineered to use microcurrent electro-therapy technology to treat the dry version of AMD.

ABOUT AMD

AGE-RELATED Macular Degeneration has no cure. It is the No. 1 cause of severe vision loss and legal blindness in adults over 60 in North America. More than 15 million North Americans suffer from this affliction — a figure that is expected to double as baby boomers age.

ABOUT NOVA OCULUS

NOVA OCULUS is the name of the pioneering new medical device engineered and developed to treat the dry form of Age-Related Macular Degeneration—and for the Canadian-American company that created it.

The Nova Oculus II device could revolutionize the treatment protocols for dry AMD and offer hope to millions of North Americans who might otherwise going blind without it. Though dry AMD is an affliction without a cure, the Nova Oculus company’s patented microcurrent electro-therapy technology can help mitigate its symptoms.

Nova Oculus Partners boasts a blue-ribbon team of highly experienced engineering professionals leading its efforts to bring Nova Oculus to market. The company has also assembled a medical advisory board that includes some of the leading optometric professionals in the United States who are assisting in developing a plan to earn FDA approval for the Nova Oculus II device and gain its widespread commercialization in the U.S. Efforts toward regulatory approval are also underway in Canada and Mexico.

The Nova Oculus II device has been certified as complying with the quality management standard set by the International Organization of Standardization (ISO) and the electrical safety standard set by the International Electrotechnical Commission (IEC). These global certifications will help pave the way for regulatory approvals for Nova Oculus in Europe and elsewhere.

For more information:
Walter O’Rourke,
519-829-8587.

Read the full story at https://www.prweb.com/releases/edmonton_to_host_clinical_trial_for_nova_oculus_medical_device_that_could_help_improve_vision_for_amd_sufferers/prweb15988887.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Bed Bugs Infest Edmonton Buses as More of Them Plague Rockford, My Cleaning Products Gives Out Samples to Help
2. Apple’s Face ID Security Available in Mobile App for Clinical Trial Management
3. MCC Announces: Dr. Jean Mulinde, CDER, FDA Confirmed Speaker at Clinical Trial Risk and Performance Management Summit, Nov. 14-15, 2018, Princeton, NJ
4. Predicine Establishes Dual CAP Accreditation for its Genomic Sequencing Laboratories in US and China to Support Global Clinical Trials
5. ACRES Testing Clinical Research Site Accreditation Process
6. Medable Wins DPharm Idol Competition for Human Digitome as a Disruptive Application in Clinical Research
7. Almac Clinical Technologies Releases New Podcast Series Entitled “Spotlight on IRT: Best Practices”
8. Mitotech Partners with Essex Bio-Technology for Late-stage Clinical Program in Dry Eye Disease
9. Clinical Study Demonstrates that RPS Diagnostics FebriDx Rapid Point-of-Care Blood Test Can Accurately Distinguish Between Acute Bacterial and Viral Respiratory Infection
10. VMS BioMarketing Clinical Nurse Educators Will Provide Education to Support Needs of Women With Breast Cancer
11. SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2019)... ... ... Cirtec Medical Corporation, a strategic outsourcing partner for complex medical devices, including active implantables ... sq. ft. manufacturing facility in the Coyol free zone, located in Alajuela, Costa ... to be fully operational by the end of the year, will be the company’s ...
(Date:7/19/2019)... (PRWEB) , ... July 18, 2019 , ... ... known as “Ravi Everest,” will be joining forces with California-based charity Coalition Duchenne ... from July 20-22nd. Coalition Duchenne raises awareness and funding for Duchenne muscular dystrophy ...
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... Today, at ... Iowa, the National Corn Growers Association (NCGA) announced the winners of the ... improve a product or process using field corn to produce biobased materials. , “Corn ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc ... application to the FDA for use of a person’s own adipose-derived stem cells to ... osteoarthritis in the knee. This IND is the first of several planned clinical ...
Breaking Biology Technology:
(Date:7/26/2019)... ... July 26, 2019 , ... Worldwide Business with ... Technologies CEO Phil Deschamps to discuss their potential new treatment option to manage ... a neurotech company in the medical device industry that's focused on neurological wellness. ...
(Date:7/23/2019)... ... July 23, 2019 , ... My Gene ... today announced that the company has expanded its database of genetic resources to ... (FH), and Parkinson’s disease. , The expanded content comes following 23andMe’s June 2019 ...
(Date:7/21/2019)... ... July 20, 2019 , ... ... Technologies ( http://www.fluidimaging.com ) announced today the release of the biggest software ... imaging and characterization platform will provide a significant increase in productivity for ...
Breaking Biology News(10 mins):